Immutep Ltd ADR (IMMP)

Currency in USD
0.649
+0.335(+106.26%)
Real-time Data·
Unusual trading volume
IMMP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.5601.050
52 wk Range
0.2933.530
Key Statistics
Prev. Close
0.315
Open
0.99
Day's Range
0.56-1.05
52 wk Range
0.293-3.53
Volume
649.71M
Average Vol. (3m)
1.44M
1-Year Change
-56.8411%
Book Value / Share
0.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMMP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Immutep Ltd ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Compare IMMP to Peers and Sector

Metrics to compare
IMMP
Peers
Sector
Relationship
P/E Ratio
−1.3x−6.6x−0.5x
PEG Ratio
0.01−0.030.00
Price / Book
1.1x2.9x2.6x
Price / LTM Sales
13.4x17.0x3.2x
Upside (Analyst Target)
217.5%159.6%47.6%
Fair Value Upside
Unlock−11.0%6.1%Unlock

Analyst Ratings

0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Hold---DowngradeMar 13, 2026
Citizens
Hold---DowngradeMar 13, 2026
Baird
Hold1.00+53.37%7.00DowngradeMar 13, 2026
Citizens
Buy6.00+820.25%-New CoverageFeb 17, 2026

Earnings

Latest Release
Feb 24, 2026
EPS / Forecast
-- / -0.15
Revenue / Forecast
-- / 190.81M
EPS Revisions
Last 90 days

IMMP Income Statement

People Also Watch

0.172
CXAI
+4.24%
3.2588
WNW
+1.84%
0.114
ISPC
+4.13%
0.704
EONR
+0.92%

FAQ

What Is the Immutep ADR (IMMP) Stock Price Today?

The Immutep ADR stock price today is 0.649 USD.

What Stock Exchange Does Immutep ADR Trade On?

Immutep ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immutep ADR?

The stock symbol for Immutep ADR is "IMMP."

What Is the Immutep ADR Market Cap?

As of today, Immutep ADR market cap is 41.030M USD.

What Is Immutep ADR's Earnings Per Share (TTM)?

The Immutep ADR EPS (TTM) is -0.057.

When Is the Next Immutep ADR Earnings Date?

Immutep ADR will release its next earnings report on Jun 03, 2026.

From a Technical Analysis Perspective, Is IMMP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Immutep ADR Stock Split?

Immutep ADR has split 1 times.

How Many Employees Does Immutep ADR Have?

Immutep ADR has 31 employees.

What is the current trading status of Immutep ADR (IMMP)?

As of Apr 15, 2026, Immutep ADR (IMMP) is trading at a price of 0.649 USD, with a previous close of 0.315 USD. The stock has fluctuated within a day range of 0.560 USD to 1.050 USD, while its 52-week range spans from 0.293 USD to 3.530 USD.

What Is the IMMP Premarket Price?

IMMP's last pre-market stock price is 0.972 USD. The pre-market share volume is 314,260,000.000, and the stock has decreased by 0.657, or 208.570%.

What Is the IMMP After Hours Price?

IMMP's last after hours stock price is 0.384 USD, the stock has decreased by 0.069, or 21.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.